Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead’s senior ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Disputes like this aren’t rampant, Padlock’s ...

Gilead Sciences named former Sanofi executive Dietmar Berger as chief medical officer, effective Jan. 2, succeeding Merdad Parsey. Berger had held the same role at Sanofi, where he was also global ...

Roche alumnus Dietmar Berger has joined Sanofi as head of development ... with cell therapies from Kite/Gilead under a deal announced in 2016 – eventually led Berger to be tempted away to ...

(Reuters) -Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who is preparing to leave early next year. Berger, ...

Dietmar Berger will join Atara as global head of R ... with cell therapies from Kite/Gilead under a deal announced in 2016. But Berger has been drawn to Atara by the potential of allogeneic ...

December 12, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of ...

Gilead appoints Sanofi official Dietmar Berger as next chief medical officer Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not ...